Alvotech Accelerates European Leadership with Multiple EMA Biosimilar Approvals, Strong Q3 Performance, and Expansion of Packaging Capabilities in 2025
Friday, November 14, 2025
Alvotech, a global biotech company specializing in biosimilars, reported robust financial and operational results for the first nine months of 2025, underlining its expanding presence and influence within the European pharmaceutical and life sciences sector. The Reykjavík-headquartered company posted total revenues of $420 million, reflecting a 24% increase from the comparable period in the previous year, and product and service revenues soared by 85% year-over-year to $237.4 million. This sharp growth is closely linked to the company’s aggressive expansion into European markets and a successful strategy focused on high-value product launches, especially biosimilars that address critical healthcare needs across the continent.
Alvotech’s Q3 2025 business update details a period characterized by strong license revenues, high gross margins, and the launch of several biosimilar products. Notably, the European Economic Area has granted marketing approval to Mynzepli®, Alvotech’s biosimilar to Eylea® (aflibercept) for ophthalmology indications, enhancing the company’s presence in the specialty therapy market. Simultaneously, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Alvotech’s biosimilar candidates to Simponi® (golimumab), Prolia® (denosumab), and Xgeva® (denosumab), signaling imminent market entry pending final authorization. EMA’s acceptance of the Marketing Authorization Application for a Xolair (omalizumab) biosimilar further deepens Alvotech’s portfolio aimed at autoimmune, oncology, and respiratory conditions.
In parallel, the company continues to invest heavily in research and development, with R&D expenses reaching $144.5 million, a 10% increase compared to the previous year. This investment supports a multi-pronged pipeline, including nine disclosed biosimilar candidates targeting autoimmune disorders, eye diseases, osteoporosis, respiratory conditions, and cancer. Key programs advancing through late-stage clinical development contributed to the upsurge in R&D expenditure, underpinning Alvotech’s commitment to delivering more affordable biologic medicines.
Manufacturing and vertical integration remain central strategic pillars. During Q3, Alvotech completed the acquisition and consolidation of Ivers-Lee, a move that not only expanded its packaging and supply capabilities but also resulted in a recognized $8 million gain for the period. This acquisition underpins future product launches and enhances internal control over crucial supply chain and packaging operations for European markets. The company’s commitment to operational excellence was underscored by actions to address regulatory findings from a July FDA inspection of its Reykjavik facility, while maintaining uninterrupted FDA-approved production for both U.S. and European supply.
Market-specific launches—such as AVT02, a Humira biosimilar now branded as HUKYNDRA in Europe, and AVT04, a Stelara biosimilar marketed as UZPRUVO in the EEA—continue to drive market share gains in the highly competitive monoclonal antibody segment. The anticipation of launching a Simponi biosimilar first in the U.K., European Economic Area, and Japan represents a strategic milestone, positioning Alvotech as a first mover in key therapy areas. Revenues from these launches are expected to form the backbone of continued growth, augmented by a robust orderbook for Q4 2025 in ex-US markets.
The outlook for the company remains confident, with revised 2025 revenue guidance projected between $570–600 million and adjusted EBITDA expected to range from $130–150 million. Management emphasizes ongoing strategic commercial partnerships throughout Europe, facilitating broad geographic market penetration and access to local expertise. As Alvotech consolidates its platform with expanded European regulatory approvals and manufacturing network, it exemplifies a European biosimilar leader leveraging innovation, operational scale, and a resilient growth strategy in a competitive sector increasingly shaped by regulatory scrutiny, health system demands for cost efficiencies, and the need for high-quality biologic treatments.
Executives cited the contribution of Joseph—Leader of R&D and pipeline development—as instrumental in achieving regulatory approvals and in maintaining standards critical for quality and compliance, especially with ongoing regulatory resolutions. Alvotech plans to issue a forward-looking business update alongside its full-year 2025 results, but current momentum signals sustained top-line and EBITDA expansion into 2026, reinforcing its commitments to accessible biosimilars and value creation for partners and health systems across Europe.
